Answers are grounded in this paper and cite their sources.
Transarterial radioembolization (TARE) is an important locoregional treatment for hepatocellular carcinoma (HCC). Herein, biodegradable ¹⁷⁷Lu-HCS-PLGA microspheres with a homogeneous core–shell (HCS) architecture were fabricated via microfluidic double-emulsion technology combined with in situ mineralization and designed for decay–degradation temporal matching. Mean microsphere-associated radioactivity retention remained above 90% through 30 days, while longer-term degradation observations documented progressive carrier erosion and fragmentation. In the H22 subcutaneous tumor model, intratumoral administration of ¹⁷⁷Lu-HCS-PLGA MSs combined with PD-1 blockade was associated with greater tumor growth inhibition and immune-related changes. Transcriptomic analysis and Batf3 -knockout experiments were used to explore the contribution of Batf3 -dependent cDC1s to treatment-associated immune changes. Separately, the beagle renal artery model was used to evaluate catheter delivery and radionuclide retention, whereas the rabbit VX2 orthotopic hepatic tumor model was used to evaluate transarterial delivery, intratumoral retention, and the 14-day local treatment response. These findings provide insights into the design of biodegradable radioactive microspheres for locoregional treatment. Fabrication and experimental evaluation of biodegradable ¹⁷⁷Lu-HCS-PLGA microspheres designed to match carrier degradation with radioactive decay. The schematic summarizes intratumoral treatment with PD-1 blockade in the H22 mouse model and separate transarterial delivery studies in the rabbit VX2 liver tumor and beagle renal artery models
No takes yet. Share an insight, caveat, or question.
Meng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: